广泛期小细胞肺癌维持治疗的研究进展

Research Progress in Maintenance Therapy of Extensive Small Cell Lung Cancer

小细胞肺癌(SCLC)是一种恶性程度较高的肿瘤,虽然一线化疗的有效率较高,但治疗后也易产生复发转移,同时还会导致患者对二线及后续的治疗不太敏感。目前针对广泛期SCLC采用细胞毒性药物、小分子靶向药物等维持治疗的研究已取得一定进展。免疫治疗为广泛期SCLC患者的治疗带来希望,一线治疗后继续应用免疫维持治疗已成为广泛期SCLC患者新的治疗策略。未来可通过维持治疗延长广泛期SCLC患者的耐药时间,进而延长患者的生命。

Small cell lung cancer(SCLC)is a tumor with a high degree of malignancy.Although the first-line chemotherapy is highly effective,it is also prone to recurrence and metastasis after the treatment,and it can also lead to patients being less sensitive to second-line and subsequent treatment.At present,some clinical studies have used cytotoxic drugs and small-molecule targeted drugs to explore maintenance therapy for extensive SCLC and has made some progress.In recent years,immunotherapy has brought new light to the treatment of extensive SCLC,and continued use of immune maintenance therapy after first-line treatment of extensive SCLC has become a new therapeutic strategy.In the future,the drug resistance time of the patients with extensive SCLC can be prolonged by maintenance treatment,thus prolonging the patient life.